tiprankstipranks
Advertisement
Advertisement

ASND Stock Latest News

Ascendis Pharma Monetizes FDA Priority Review Voucher for $187.5 Million
Company AnnouncementsAscendis Pharma Monetizes FDA Priority Review Voucher for $187.5 Million
3d ago
6K
ASND
Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism
PremiumCompany Announcements
Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism
6d ago
6K
ASND
Ascendis Pharma completes Phase 3 PaTHway Trial
PremiumThe Fly
Ascendis Pharma completes Phase 3 PaTHway Trial
6d ago
ASND
Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism
PremiumCompany Announcements
Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism
9d ago
6K
ASND
Ascendis Pharma announces five-year data from PaTH Forward Trial
PremiumThe Fly
Ascendis Pharma announces five-year data from PaTH Forward Trial
9d ago
ASND
Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan
PremiumCompany AnnouncementsAscendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan
10d ago
6K
ASND
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
Premium
The Fly
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
11d ago
ASND
BMRN
Analyst Reiterates Buy on Ascendis Pharma, Keeps $288 Price Target Amid ITC Uncertainty and Strong Yorvipath Rollout
Premium
Ratings
Analyst Reiterates Buy on Ascendis Pharma, Keeps $288 Price Target Amid ITC Uncertainty and Strong Yorvipath Rollout
20d ago
ASND
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
PremiumThe Fly
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
1M ago
AMT
BAP
Ascendis Pharma initiated with a Buy at Citi
PremiumThe Fly
Ascendis Pharma initiated with a Buy at Citi
1M ago
ASND
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI
PremiumThe Fly
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI
1M ago
ASND
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants
PremiumCompany Announcements
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants
1M ago
6K
ASND
Ascendis Pharma price target raised to $345 from $342 at Barclays
PremiumThe FlyAscendis Pharma price target raised to $345 from $342 at Barclays
1M ago
ASND
Ascendis Pharma Earnings Call Highlights Growth Momentum
Premium
Company Announcements
Ascendis Pharma Earnings Call Highlights Growth Momentum
1M ago
ASND
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
Premium
The Fly
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
1M ago
ASND
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count
PremiumRatings
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count
1M ago
ASND
Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15)
PremiumThe Fly
Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15)
1M ago
ASND
Ascendis Pharma Swings to €629 Million Q1 2026 Profit on Strong Revenue Growth
PremiumCompany Announcements
Ascendis Pharma Swings to €629 Million Q1 2026 Profit on Strong Revenue Growth
1M ago
6K
ASND
Ascendis Pharma Q1 2026 Results Highlight YORVIPATH Growth and U.S. Launch of YUVIWEL
PremiumCompany Announcements
Ascendis Pharma Q1 2026 Results Highlight YORVIPATH Growth and U.S. Launch of YUVIWEL
1M ago
6K
ASND
Ascendis Pharma Calls Full Redemption of $575 Million 2028 Convertible Notes After Share Price Surge
PremiumCompany AnnouncementsAscendis Pharma Calls Full Redemption of $575 Million 2028 Convertible Notes After Share Price Surge
2M ago
6K
ASND
Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares
Premium
Company Announcements
Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares
2M ago
6K
ASND
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading
Premium
Company Announcements
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading
2M ago
6K
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >